# Cannabinoids & Statins & Lipid-Lowering Agents: Evidence, Pharmacokinetics & Safety Review > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoid-interactions-statins-lipid-lowering-agents-evidence/ > **Published:** 2026-10-17T10:18:55-04:00 | **Last Modified / Clinically Audited:** 2026-10-17T10:18:55-04:00 > **Clinical Summary:** Pharmacology & Safety Series Clinically Audited: October 2026 Cannabinoids & Statins & Lipid-Lowering Agents: Evidence, Pharmacokinetics & Safety Review Author & Reviewer: Benjamin Caplan, MD • Family Medicine & Cannabinoid Specialist Clinical Bottom Line for Patients & Prescribers Cannabinoids interact with statins & lipid-lowering agents primarily through Competitive inhibition of CYP3A4, potentially increasing circulating statin […] --- Pharmacology & Safety Series Clinically Audited: October 2026 Table of Contents - [Cannabinoids & Statins & Lipid-Lowering Agents: Evidence, Pharmacokinetics & Safety Review](#Cannabinoids_038_Statins_038_Lipid-Lowering_Agents_Evidence_Pharmacokinetics_038_Safety_Review)[1. The Primary Pharmacokinetic Mechanism](#1_The_Primary_Pharmacokinetic_Mechanism)[Development of lipid-based nanoparticles formulation loaded with potential anticancer active compounds for future glioblastoma therapy](#Development_of_lipid-based_nanoparticles_formulation_loaded_with_potential_anticancer_active_compounds_for_future_glioblastoma_therapy) - [Managing Interactions Without Therapeutic Compromise](#Managing_Interactions_Without_Therapeutic_Compromise)[Does cannabis or CBD interact with Statins & Lipid-Lowering Agents?](#Does_cannabis_or_CBD_interact_with_Statins_038_Lipid-Lowering_Agents) - [What monitoring or laboratory surveillance is required when taking cannabinoids alongside Statins & Lipid-Lowering Agents?](#What_monitoring_or_laboratory_surveillance_is_required_when_taking_cannabinoids_alongside_Statins_038_Lipid-Lowering_Agents) - [Related](#Related) # Cannabinoids & Statins & Lipid-Lowering Agents: Evidence, Pharmacokinetics & Safety Review **Author & Reviewer:** [Benjamin Caplan, MD](https://cedclinic.com/drcaplan/) • Family Medicine & Cannabinoid Specialist Clinical Bottom Line for Patients & Prescribers Cannabinoids interact with statins & lipid-lowering agents primarily through Competitive inhibition of CYP3A4, potentially increasing circulating statin concentrations and elevating risk of myopathy. Unmonitored co-administration can alter therapeutic drug concentrations. Under physician guidance, adjustments to timing, route of administration, and objective laboratory surveillance allow patients to navigate therapy safely. ## 1. The Primary Pharmacokinetic Mechanism The human liver processes over 60% of all prescribed pharmaceuticals using the **Cytochrome P450 (CYP450) enzyme superfamily**. Cannabinoids—most notably cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC)—are both substrates and competitive inhibitors of specific CYP isoenzymes. Enzyme Pathway Dynamics **Mechanism:** Competitive inhibition of CYP3A4, potentially increasing circulating statin concentrations and elevating risk of myopathy. **Medications Impacted:** Atorvastatin (Lipitor), Simvastatin (Zocor), Rosuvastatin (Crestor). Featured Peer-Reviewed Investigation CLOK (University of Central Lancashire) (2027) ### Development of lipid-based nanoparticles formulation loaded with potential anticancer active compounds for future glioblastoma therapy **Lead Investigators:** Mustafa Adnan ali Ali | **Identifier:** Clinical Citation **Study Findings & Abstract:** Cancer is responsible for approximately one out of every six deaths worldwide, making it a significant contributor to global mortality. There are approximately three million people living with cancer in the UK and the number predicted to increase by half a million by 2025. Glioblastoma (GB) is a grade IV brain tumours, it stands as the most prevalent and devastating form of brain tumours. Patients diagnosed with GB have a median survival of only 14.6 months following conventional treatment plan of surgery, radiation and chemotherapy. Passing through the blood-brain barrier (BBB) remain as a challenge when treating GBs, in addition to other limitation of the current treatment. Therefore, there is a need to develop a new carrier system, like nanoparticles (NPs) to improve the drug delivery. NPs can potentially overcome the challenges posed by the BBB, enhance the targeting of glioma stem cells, and reduce the side effects associated with conventional treatments. This project aims to develop lipid-based NPs using two formulation techniques: high-speed homogenization for nanostructured lipid carriers (NLCs) and microfluidics for lipid nanoparticles (LNPs). The formulations were loaded with epigallocatechin gallate (EGCG), a phytochemical which has anti-cancer properties, aiming to potentially bypass the BBB and target glioblastoma cells. The developed NPs were assessed for size, polydispersity index, and zeta potential using dynamic light scattering (DLS) Zetasizer. The developed EGCG NLC has a particle size of 174.06 (nm) with a PDI of 0.201, and zeta potential of –4.28 mV, while EGCG LNP has a particle size of 147.96 (nm) with a PDI of 0.261 and a zeta potential of –24.6 mV. The EGCG loaded into the NPs was quantified using a newly developed and validated HPLC method where the NLC total drug was 81.08 % and for the LNP total drug was 79.56 %. Stability studies were conducted over one month on NLC formulations, evaluating physiochemical properties. The EGCG NLC that demonstrated superior results was selected. In colloidal stability study, across various media, water provided the best stability for both EGCG NLC and EGCG LNP formulations. Future work, evaluation of the efficacy of the developed NPs formulations, in-vitro cell proliferation assay assessment on the U87MG (human glioblastoma cell lines) and SVG P12 (human, non-cancerous foetal glial line) cell lines. This research provides a foundation for future studies aiming to enhance drug delivery to GBs and potentially improve therapeutic outcomes. [Access PubMed / DOI Reference Record →](https://doi.org/10.17030/uclan.thesis.00059033) Dr. Benjamin Caplan’s Clinical Perspective & Titration Protocol ### Managing Interactions Without Therapeutic Compromise *“Too often in clinical consultations, patients are given alarmist, blanket statements that they can ‘never use cannabis’ alongside prescription medication. In truth, pharmacology is a science of doses, affinities, and kinetics. When co-managing patients on statins & lipid-lowering agents, the goal is never to guess. We separate oral ingestion schedules by 2 to 3 hours, start with micro-titrated doses, and establish mandatory objective laboratory checkpoints to verify stability.”* **Mandatory Clinical Monitoring:** Creatine kinase (CK) levels if muscle soreness occurs, alongside routine annual lipid panels and hepatic transaminases. **Clinical Authority Context:** Dr. Benjamin Caplan, MD has overseen more than 350,000 patient evaluations across his career (including supervising 250,000+ patients as former Chief Medical Officer of Canna Care Docs). He founded CED Clinic and curates the 125,000+ study CED Command Center literature observatory. Frequently Asked Clinical Questions • Direct Answers #### Does cannabis or CBD interact with Statins & Lipid-Lowering Agents? Cannabinoids interact with statins & lipid-lowering agents primarily through Competitive inhibition of CYP3A4, potentially increasing circulating statin concentrations and elevating risk of myopathy. Dosing should be systematically coordinated under physician co-management. #### What monitoring or laboratory surveillance is required when taking cannabinoids alongside Statins & Lipid-Lowering Agents? Creatine kinase (CK) levels if muscle soreness occurs, alongside routine annual lipid panels and hepatic transaminases. Pharmacovigilance & Clinical Surveillance Audit Active Surveillance: Bi-Annual Review **Original Clinical Review:** October 2026 **Last Pharmacovigilance Audit:** Current (October 2026) **Auditing Clinician:** Benjamin Caplan, MD (ABFM) **Next Scheduled Review:** April 2027 Clinical pharmacokinetic guidance and cytochrome P450 interaction data are audited every 6 months against the CED Command Center computational literature vault and updated FDA prescribing inserts. Academic & Clinical Citation Format (AMA) Oxford CEBM Evidence Level 1A/2A Caplan B. Cannabinoids & Statins & Lipid-Lowering Agents: Evidence, Pharmacokinetics & Safety Review. *CED Clinic Medication Safety & Pharmacology Series*. Published October 2026. https://cedclinic.com/cannabinoid-interactions-statins-lipid-lowering-agents-evidence/ [View Dr. Caplan’s Research & Bio →](https://cedclinic.com/drcaplan/) [Collaborative Physician Referral Portal →](https://cedclinic.com/physician-referral/) [Complex Medication Advisory →](https://cedclinic.com/advisor/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).